Following oral administration of 1–6 mg rivastigmine twice daily, AChE activity is suppressed in a dose-dependent fashion within the CSF of individuals with Alzheimer’s disease (Cutler et al. 1998). Here, ACHE is linked to early-onset autosomal dominant Alzheimer disease.